Dubai:The United Arab Emirates is solidifying its position as one of the most advanced clinical diagnostics markets in the region. This progress is driven by substantial investments in genomics, integrated laboratory networks, artificial intelligence, regulation, and reimbursement, which are bridging the gap from scientific innovation to routine patient care. These developments are part of the insights presented at the World Health Expo (WHX) 2027, scheduled to open in Dubai on January 25, 2027.
According to Wam, the WHX series report, created in collaboration with Frost and Sullivan, forecasts that the global clinical diagnostics market will grow from $115.7 billion in 2026 to $152.1 billion by 2031, with a compound annual growth rate of 5.5 percent. The UAE distinguishes itself not only through its investments in advanced technologies but also in its ambition to scale their deployment. The nation is advancing genomics, laboratory infrastructure, AI-enabled diagnostics, and reimbursement simultaneously to enhance healthcare systems and translate innovations into tangible patient benefits.
The Middle East market is projected to be valued at $5.4 billion in 2026, with the UAE gaining strategic importance through its strengths in molecular diagnostics, decentralized testing, and AI-enabled pathology. The country's investment in genomic infrastructure, such as the Emirati Genome Programme, supports personalized healthcare and research by building population-level genomic datasets. Additionally, Cleveland Clinic Abu Dhabi offers precision oncology services, next-generation sequencing, genetic counseling, and hereditary cancer testing.
Since January 2025, genetic testing has been mandatory for Emiratis as part of premarital screening, covering 570 genes associated with over 840 genetic conditions. Reimbursement in the UAE has also expanded to include oncology next-generation sequencing and companion diagnostics. Frost and Sullivan predict the global molecular diagnostics segment will grow from $26.9 billion in 2026 to $36 billion by 2031, driven by oncology molecular profiling, companion diagnostics, and infectious disease surveillance.
The UAE is also broadening access to diagnostics and enhancing laboratory infrastructure. PureHealth's PureLab, the country's largest integrated laboratory network, conducted 34 million tests in 2025, marking a 17 percent increase from 2024. This shift towards centralizing laboratory capacity and bringing testing closer to patients is one of the most significant changes in global diagnostics. Point-of-care testing is expected to grow from $19.1 billion in 2026 to $26.2 billion by 2031, as rapid testing platforms become more prevalent in urgent care and community settings.
Frost and Sullivan's analysis highlights changes in the procurement of diagnostic technologies, with large hospital groups and integrated primary care networks emerging as key customers. Connectivity, remote quality monitoring, and laboratory information system integration are becoming standard requirements in GCC tenders, reshaping how the laboratory industry interacts with the broader healthcare market.
The WHX will be held from January 25 to 28, 2027, at the Dubai Exhibition Centre, Expo City Dubai, and Dubai World Trade Centre. The event is expected to attract more than 90,000 attendees, 4,200 exhibitors, and representatives from over 195 countries.